Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. increased its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,907 shares of the company's stock after buying an additional 10,243 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of Vaxcyte worth $6,132,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in Vaxcyte during the second quarter valued at approximately $70,000. American Century Companies Inc. lifted its holdings in shares of Vaxcyte by 14.3% during the 2nd quarter. American Century Companies Inc. now owns 527,594 shares of the company's stock valued at $39,839,000 after acquiring an additional 65,870 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Vaxcyte during the 2nd quarter worth $277,000. Envestnet Asset Management Inc. boosted its position in Vaxcyte by 12.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 47,961 shares of the company's stock worth $3,622,000 after purchasing an additional 5,268 shares during the period. Finally, Mutual of America Capital Management LLC increased its holdings in Vaxcyte by 13.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 50,813 shares of the company's stock valued at $3,837,000 after purchasing an additional 6,114 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the business's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 2,366 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now owns 137,398 shares of the company's stock, valued at $14,274,278.22. This represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 113,732 shares of company stock valued at $11,730,787 over the last three months. 3.10% of the stock is owned by insiders.

Vaxcyte Trading Up 0.0 %

PCVX stock traded up $0.02 during midday trading on Friday, hitting $81.08. 1,022,649 shares of the company's stock were exchanged, compared to its average volume of 942,108. The firm has a 50 day moving average price of $90.20 and a 200-day moving average price of $93.40. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The stock has a market capitalization of $10.11 billion, a price-to-earnings ratio of -17.63 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on PCVX shares. Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.